Bonum Therapeutics is a technology company.
Bonum Therapeutics has raised $93.0M across 1 funding round.
Bonum Therapeutics has raised $93.0M in total across 1 funding round.
Bonum Therapeutics has raised $93.0M in total across 1 funding round.
Bonum Therapeutics's investors include Codon Capital, Digitalis Ventures, RiverVest, Roche Venture Fund.
Bonum Therapeutics is a Seattle-based biotechnology company developing a proprietary technology platform for antibody-regulated biologics that enable precision activation of therapies, primarily targeting oncology with potential expansion into autoimmunity, metabolic disorders, and pain management.[1][2][3] The platform creates conditionally active molecules that "switch on" only in targeted disease environments, aiming to deliver highly active treatments with reduced toxicity and improved safety profiles; two programs are currently in preclinical development.[1][2][4]
This approach builds on validated technology from its predecessor, Good Therapeutics, which was acquired by Roche in 2022 for a PD-1-regulated IL-2 program, demonstrating early proof of concept for safer, more effective biologics in hard-to-treat areas.[1]
Bonum Therapeutics emerged from the technology and expertise of Good Therapeutics, a predecessor company acquired by Roche in 2022, carrying forward pioneering work on conditionally active therapeutic agents—biologics engineered to activate precisely in disease sites.[1][4] Headquartered in Seattle, Washington, the company focuses on antibody-based mechanisms for regulated, targeted medicines, with oncology as its initial priority area.[2]
While specific founders are not detailed in available sources, Bonum was established post-acquisition to independently advance this platform, leveraging the Roche-validated IL-2 program as a foundational milestone that provided early traction and de-risked the core technology.[1]
Bonum Therapeutics rides the wave of precision oncology and conditional biologics, a trend accelerating with advances in antibody engineering and targeted therapies amid rising demand for safer immunotherapies beyond PD-1/PD-L1 inhibitors.[1][4] Timing aligns with post-2022 biopharma shifts toward platforms enabling tissue-specific activation, fueled by market forces like high cancer prevalence, regulatory emphasis on reduced adverse events, and investor interest in de-risked assets from prior exits like Roche's acquisition.[1]
By influencing the ecosystem through preclinical advancements, Bonum contributes to next-gen biologics that could reshape treatment paradigms, potentially partnering with or attracting big pharma seeking bolt-on innovations in immunology and beyond.[2][3]
Bonum is poised to advance its two preclinical programs toward IND filings, potentially expanding the platform to additional indications as data emerges, with key catalysts including proof-of-concept studies and partnerships mirroring its predecessor's Roche deal.[1][2] Trends like AI-aided drug design and combo immunotherapy will shape its path, amplifying platform scalability amid a biotech funding rebound favoring validated tech.[4]
As a post-acquisition spinout, Bonum's influence could evolve through milestone-driven growth, positioning it as a leader in safer targeted biologics and delivering on the promise of precision activation that began with its foundational Roche-validated assets.[1]
Bonum Therapeutics has raised $93.0M across 1 funding round. Most recently, it raised $93.0M Series A in November 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2022 | $93.0M Series A | Codon Capital, Digitalis Ventures, RiverVest, Roche Venture Fund |